[Patient with TNBC with early relapse within 12 months from adjuvant treatment.] / Paziente affetta da TNBC con ricaduta precoce entro 12 mesi dal trattamento adiuvante.

ABSTRACT

Triple negative disease, defined by a lack of tumor cell expression of estrogen receptor, progesterone receptor and HER2, remains to date the worst prognosis subtype and especially in metastatic disease triple negative breast cancer is still un unmet clinical need. However, even in this setting, now we can use new drugs such as immunotherapy and antibodies drug conjugated to improve outcome. Particularly, sacituzumab govitecan is the first Ab drug conjugated demonstrating a significant improvement in terms of overall and progression free survival in patients affected by metastatic TNBC pretreated with 2-3 previous lines of therapy.